Acute
The medications prescribed for acute toxoplasmosis are the following:

Pyrimethamine – an antimalarial medication
Sulfadiazine – an antibiotic used in combination with pyrimethamine to treat toxoplasmosis
Combination therapy is usually given with folic acid supplements to reduce incidence of thrombocytopaenia. Combination therapy is most useful in the setting of HIV. Clindamycin
Spiramycin – an antibiotic used most often for pregnant women to prevent the infection of their children. (other antibiotics, such as minocycline, have seen some use as a salvage therapy). If infected during pregnancy, spiramycin is recommended in the first and early second trimesters while pyrimethamine/sulfadiazine and leucovorin is recommended in the late second and third trimesters. Latent
In people with latent toxoplasmosis, the cysts are immune to these treatments, as the antibiotics do not reach the bradyzoites in sufficient concentration. The medications prescribed for latent toxoplasmosis are:

Atovaquone – an antibiotic that has been used to kill Toxoplasma cysts inside AIDS patients
Clindamycin – an antibiotic that, in combination with atovaquone, seemed to optimally kill cysts in mice

Congenital
When a pregnant woman is diagnosed with acute toxoplasmosis, amniocentesis can be used to determine whether the fetus has been infected or not. When a pregnant woman develops acute toxoplasmosis, the tachyzoites have approximately a 30% chance of entering the placental tissue, and from there entering and infecting the fetus. As gestational age at the time of infection increases, the chance of fetal infection also increases.If the parasite has not yet reached the fetus, spiramycin can help to prevent placental transmission.
In December 2008, the U.S. Food and Drug Administration (FDA) declined to approve oritavancin without additional studies, and an EU application was withdrawn. In 2009, The Medicines Company acquired the development rights, completed clinical trials and submitted a new drug application to the FDA in February 2014. On August 6, 2014, the  United States FDA approved oritavancin to treat skin infections.A marketing authorisation valid throughout the European Union was granted on 19 March 2015, for the treatment of acute bacterial skin and skin structure infections in adults. References
External links
"Oritavancin". Drug Information Portal. U.S. National Library of Medicine.